Magnesium for Antidepressant Discontinuation Symptoms
There is no evidence supporting magnesium supplementation for alleviating antidepressant discontinuation symptoms. While magnesium has demonstrated benefits in treating active depression, no studies have investigated its role in managing withdrawal symptoms that occur when stopping antidepressants.
Evidence for Magnesium in Depression vs. Discontinuation
What We Know About Magnesium and Active Depression
Magnesium supplementation improves depressive symptoms when used as adjunctive treatment alongside antidepressants, with significant benefits appearing after 4-6 weeks of supplementation at doses of 120 mg/day or higher 1, 2.
Meta-analyses confirm antidepressant effects of magnesium in adults with depressive disorders, showing standardized mean differences of -0.919 in depression scores compared to placebo 3.
Magnesium modulates neurotransmitter systems relevant to depression, including glutamatergic and GABAergic pathways, and influences the hypothalamic-pituitary-adrenal axis involved in stress responses 4.
The Critical Gap: No Evidence for Discontinuation Symptoms
Antidepressant discontinuation syndrome is a distinct clinical entity characterized by dizziness (most prevalent symptom with 6.24% risk difference), nausea, vertigo, and nervousness—not mood worsening 5.
Guidelines recognize withdrawal symptoms occur with abrupt antidepressant cessation, particularly with paroxetine and venlafaxine, but do not mention magnesium as a treatment option 6.
The pathophysiology differs: Discontinuation symptoms involve acute neurotransmitter rebound and receptor adaptation, while magnesium's demonstrated benefits target chronic depressive pathophysiology through different mechanisms 7, 8.
What Actually Works for Discontinuation Symptoms
Slow tapering plus psychological support is the evidence-based approach for preventing antidepressant discontinuation symptoms 9:
Slow tapering (>4 weeks) with psychological support reduces relapse risk by 60% compared to abrupt discontinuation (RR 0.40, NNT 4.3) 9.
Continuation at standard dose remains more effective than any discontinuation strategy for preventing relapse (RR 0.51 vs. abrupt stopping) 9.
Fast tapering (≤4 weeks) provides insufficient protection and performs similarly to abrupt discontinuation in terms of relapse prevention 9.
Clinical Bottom Line
Do not recommend magnesium specifically for antidepressant discontinuation symptoms. The evidence base for magnesium addresses active depression treatment, not withdrawal management 1, 2, 3.
Instead, implement gradual dose reduction over more than 4 weeks combined with structured psychological support to minimize discontinuation symptoms 9. If depressive symptoms emerge weeks after discontinuation, this represents relapse rather than withdrawal and may warrant treatment—potentially including magnesium as adjunctive therapy if restarting antidepressants 5, 4.
The most common discontinuation symptoms (dizziness, nausea, vertigo) have no established connection to magnesium deficiency mechanisms 5, making biological plausibility for benefit extremely low despite magnesium's role in mood regulation 7, 8.